jacob and co roulette watch

Stocks closed higher on Wall Street as the market posted its fifth straight gain and the Dow Jones Industrial Average notched another record high. The S&P 500 rose 0.3%. The benchmark index’s 1.7% gain for the week erased most of its loss from last week. The Dow rose 1% as it nudged past its most recent high set last week, and the Nasdaq composite rose 0.2%. Markets have been volatile over the last few weeks, losing ground in the runup to elections in November, then surging following Donald Trump's victory, before falling again. The S&P 500 has been steadily rising throughout this week to within close range of its record. It's now within about 0.5% of its all-time high set last week. “Overall, market behavior has normalized following an intense few weeks,” said Mark Hackett, chief of investment research at Nationwide, in a statement. Several retailers jumped after giving Wall Street encouraging financial updates. Gap soared 12.8% after handily beating analysts' third-quarter earnings and revenue expectations, while raising its own revenue forecast for the year. Discount retailer Ross Stores rose 2.2% after raising its earnings forecast for the year. EchoStar fell 2.8% after DirecTV called off its purchase of that company's Dish Network unit. Smaller company stocks had some of the biggest gains. The Russell 2000 index rose 1.8%. A majority of stocks in the S&P 500 gained ground, but those gains were kept in check by slumps for several big technology companies. Nvidia fell 3.2%. Its pricey valuation makes it among the heaviest influences on whether the broader market gains or loses ground. The company has grown into a nearly $3.6 trillion behemoth because of demand for its chips used in artificial-intelligence technology. Intuit, which makes TurboTax and other accounting software, fell 5.7%. It gave investors a quarterly earnings forecast that fell short of analysts’ expectations. Facebook owner Meta Platforms fell 0.7% following a decision by the Supreme Court to allow a multibillion-dollar class action investors’ lawsuit to proceed against the company. It stems from the privacy scandal involving the Cambridge Analytica political consulting firm. All told, the S&P 500 rose 20.63 points to 5,969.34. The Dow climbed 426.16 points to 44,296.51, and the Nasdaq picked up 42.65 points to close at 2,406.67. European markets closed mostly higher and Asian markets ended mixed. Crude oil prices rose. Treasury yields held relatively steady in the bond market. The yield on the 10-year Treasury fell to 4.41% from 4.42% late Thursday. In the crypto market, bitcoin hovered around $99,000, according to CoinDesk. It has more than doubled this year and first surpassed the $99,000 level on Thursday. Retailers remained a big focus for investors this week amid close scrutiny on consumer spending habits headed into the holiday shopping season. Walmart, the nation's largest retailer, reported a quarter of strong sales and gave investors an encouraging financial forecast. Target, though, reported weaker earnings than analysts' expected and its forecast disappointed Wall Street. Consumer spending has fueled economic growth, despite a persistent squeeze from inflation and high borrowing costs. Inflation has been easing and the Federal Reserve has started trimming its benchmark interest rates. That is likely to help relieve pressure on consumers, but any major shift in spending could prompt the Fed to reassess its path ahead on interest rates. Also, any big reversals on the rate of inflation could curtail spending. Consumer sentiment remains strong, according to the University of Michigan's consumer sentiment index. It revised its latest figure for November to 71.8 from an initial reading of 73 earlier this month, though economists expected a slight increase. It's still up from 70.5 in October. The survey also showed that consumers' inflation expectations for the year ahead fell slightly to 2.6%, which is the lowest reading since December of 2020. Wall Street will get another update on how consumers feel when the business group The Conference Board releases its monthly consumer confidence survey on Tuesday. A key inflation update will come on Wednesday when the U.S. releases its October personal consumption expenditures index. The PCE is the Fed's preferred measure of inflation and this will be the last PCE reading prior to the central bank's meeting in December.jacob and co roulette watch 。

Sean ‘Diddy’ Combs’ third bid to be released on bail won’t be decided until next weekDuke's Diaz: QB Murphy faces internal discipline for raising middle fingers in Virginia Tech win

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Like what you see? You can subscribe here . 24/7 San Diego news stream: Watch NBC 7 free wherever you are New highs for S&P and Nasdaq U.S. markets were mixed on Monday . The S&P 500 and Nasdaq Composite climbed to new highs, but the Dow Jones Industrial Average dipped. Asia-Pacific stocks traded higher on Tuesday . Japan's Nikkei 225 jumped around 2.1%, buoyed by chip-related stocks such as Tokyo Electron and Lasertec , which shrugged off new rounds of U.S. export curbs . Intel CEO ousted Intel ousted CEO Pat Gelsinger over the weekend. The decision, made public Monday, was motivated by the board's lack of confidence in Gelsinger's plans, said a source. Replacing him as interim co-CEOs are CFO David Zinsner and products CEO MJ Holthaus. Gelsinger was named CEO in 2021, but couldn't turnaround the struggling company. Trump pledges to block U.S. Steel acquisition U.S. President-elect Donald Trump vowed to block the acquisition of U.S Steel by Japan's Nippon Steel , in a Monday post on his social platform Truth Social. The two companies reached a $14.9 billion deal in December. The U.S. Committee on Foreign Investment is reviewing the deal to ensure it doesn't incur national security risks. $56 billion package for Musk denied Tesla CEO Elon Musk failed to get his $56 billion 2018 pay package reinstated. A Delaware judge upheld her prior ruling that the compensation plan was improperly granted. Tesla shareholders had voted in June to "ratify" the package. The judge, however, wrote in her opinion that "Even if a shareholder vote could have a ratifying effect, it could not do so here." [PRO] Goldman's refreshed conviction list Goldman Sachs maintains a "Conviction List," which contains stocks it expects to perform better than the S&P. The Wall Street bank just refreshed its list of global stocks, including three it gave potential upside of more than 40% . Money Report European markets set for higher open but France's political upheaval is in focus Trump repeats vow to ‘block' Nippon Steel's bid for U.S. Steel Investors are still buzzing with positive sentiment, pushing stocks up to new records, but some analysts are concerned the good feelings are on frail footing. The S&P 500 added 0.24% and the Nasdaq Composite , electrified by Tesla's 3.5% rise and Super Micro Computer's 29% surge , climbed 0.97%. Both indexes closed at fresh highs. The Dow Jones Industrial Average slipped 0.29%, though it briefly breached the 45,000 level during the day. "The holiday season is in full swing and spirits seem bright, at least among investors," UBS wrote in a Monday note. Indeed, 56.4% of consumers expect stock prices to rise over the next year, according to a survey by The Conference Board. That's the highest level on record. Not to be a downer this holiday season, but analysts see signs that optimism might have some roots in wonderland. Stocks might have had an incredible rally in November , but that was probably investors "pric[ing] in the upside from the new, pro-business administration," Jay Hatfield, founder and CEO of InfraCap, told CNBC. Now, investors "need to get details — not just tweets — but details of what the policy is," Hatfield added, suggesting the upward momentum might take a pause for now. Investment bank Oppenheimer also noted that stocks are still expensive. "Benchmarks [are] showing forward PE multiples that are higher than their five-year averages," wrote chief investment strategist John Stoltzfus on Monday. UBS thinks the exuberance among investors is "raising concern about the markets getting frothy." Froth implies that things will settle down, which is not necessarily a bad thing in the long run. Oppenheimer, though, thinks the bull market is "driven by fundamentals" that will steer it higher in the next year, despite high valuations. Likewise, Savita Subramanian, head of U.S. equity and strategy at Bank of America, sees "ample reason to stick with stocks over bonds for the long-term." The layer of frothy milk adds to a cappuccino's delight, after all, and doesn't detract from the coffee below. — CNBC's Lisa Kailai Han, Alex Harring and Pia Singh contributed to this report. Also on CNBC Investors are filled with the holiday spirit The stock market had a November to remember November was a month to remember for stocksLAS VEGAS — Formula 1 on Monday at last said it will expand its grid in 2026 to make room for an American team that is partnered with General Motors. "As the pinnacle of motorsports, F1 demands boundary-pushing innovation and excellence. It's an honor for General Motors and Cadillac to join the world's premier racing series, and we're committed to competing with passion and integrity to elevate the sport for race fans around the world," GM President Mark Reuss said. "This is a global stage for us to demonstrate GM's engineering expertise and technology leadership at an entirely new level." The approval ends years of wrangling that launched a U.S. Justice Department investigation into why Colorado-based Liberty Media, the commercial rights holder of F1, would not approve the team initially started by Michael Andretti. Andretti in September stepped aside from leading his namesake organization, so the 11th team will be called Cadillac F1 and be run by new Andretti Global majority owners Dan Towriss and Mark Walter. The team will use Ferrari engines its first two years until GM has a Cadillac engine built for competition in time for the 2028 season. Towriss is the the CEO and president of Group 1001 and entered motorsports via Andretti's IndyCar team when he signed on financial savings platform Gainbridge as a sponsor. Towriss is now a major part of the motorsports scene with ownership stakes in both Spire Motorsports' NASCAR team and Wayne Taylor Racing's sports car team. Walter is the chief executive of financial services firm Guggenheim Partners and the controlling owner of both the World Series champion Los Angeles Dodgers and Premier League club Chelsea. "We're excited to partner with General Motors in bringing a dynamic presence to Formula 1," Towriss said. "Together, we're assembling a world-class team that will embody American innovation and deliver unforgettable moments to race fans around the world." Mario Andretti, the 1978 F1 world champion, will have an ambassador role with Cadillac F1. But his son, Michael, will have no official position with the organization now that he has scaled back his involvement with Andretti Global. "The Cadillac F1 Team is made up of a strong group of people that have worked tirelessly to build an American works team," Michael Andretti posted on social media. "I'm very proud of the hard work they have put in and congratulate all involved on this momentous next step. I will be cheering for you!" The approval has been in works for weeks but was held until after last weekend's Las Vegas Grand Prix to not overshadow the showcase event of the Liberty Media portfolio. Max Verstappen won his fourth consecutive championship in Saturday night's race, the third and final stop in the United States for the top motorsports series in the world. Grid expansion in F1 is both infrequent and often unsuccessful. Four teams were granted entries in 2010 that should have pushed the grid to 13 teams and 26 cars for the first time since 1995. One team never made it to the grid and the other three had vanished by 2017. There is only one American team on the current F1 grid — owned by California businessman Gene Haas — but it is not particularly competitive and does not field American drivers. Andretti's dream was to field a truly American team with American drivers. The fight to add this team has been going on for three-plus years, and F1 initially denied the application despite approval from F1 sanctioning body FIA. The existing 10 teams, who have no voice in the matter, also largely opposed expansion because of the dilution in prize money and the billions of dollars they've already invested in the series. Andretti in 2020 tried and failed to buy the existing Sauber team. From there, he applied for grid expansion and partnered with GM, the top-selling manufacturer in the United States. The inclusion of GM was championed by the FIA and president Mohammed Ben Sulayem, who said Michael Andretti's application was the only one of seven applicants to meet all required criteria to expand F1's current grid. "General Motors is a huge global brand and powerhouse in the OEM world and is working with impressive partners," Ben Sulayem said Monday. "I am fully supportive of the efforts made by the FIA, Formula 1, GM and the team to maintain dialogue and work towards this outcome of an agreement in principle to progress this application." Despite the FIA's acceptance of Andretti and General Motors from the start, F1 wasn't interested in Andretti — but did want GM. At one point, F1 asked GM to find another team to partner with besides Andretti. GM refused and F1 said it would revisit the Andretti application if and when Cadillac had an engine ready to compete. "Formula 1 has maintained a dialogue with General Motors, and its partners at TWG Global, regarding the viability of an entry following the commercial assessment and decision made by Formula 1 in January 2024," F1 said in a statement. "Over the course of this year, they have achieved operational milestones and made clear their commitment to brand the 11th team GM/Cadillac, and that GM will enter as an engine supplier at a later time. Formula 1 is therefore pleased to move forward with this application process." Yet another major shift in the debate over grid expansion occurred earlier this month with the announced resignation of Liberty Media CEO Greg Maffei, who was largely believed to be one of the biggest opponents of the Andretti entry. "With Formula 1's continued growth plans in the US, we have always believed that welcoming an impressive US brand like GM/Cadillac to the grid and GM as a future power unit supplier could bring additional value and interest to the sport," Maffei said. "We credit the leadership of General Motors and their partners with significant progress in their readiness to enter Formula 1."

Call for Compassionate Pardons by Rep. Jeffries

Blue Jays predicted to sign 4-time All-Star to blockbuster $225 million deal | Sporting NewsNeurofibromatosis Type 2 Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments | Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, SpringWorks 12-12-2024 08:07 PM CET | Health & Medicine Press release from: DelveInsight Business Research (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Neurofibromatosis Type 2 pipeline constitutes 5+ key companies continuously working towards developing 5+ Neurofibromatosis Type 2 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Neurofibromatosis Type 2 Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neurofibromatosis Type 2 Market. The Neurofibromatosis Type 2 Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. Some of the key takeaways from the Neurofibromatosis Type 2 Pipeline Report: https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr •Companies across the globe are diligently working toward developing novel Neurofibromatosis Type 2 treatment therapies with a considerable amount of success over the years. •Neurofibromatosis Type 2 companies working in the treatment market are Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics, AstraZeneca, Fosun Pharmaceutical, NFlection Therapeutics, Inc., and others, are developing therapies for the Neurofibromatosis Type 2 treatment •Emerging Neurofibromatosis Type 2 therapies in the different phases of clinical trials are- REC-2282, VT3989, HLX-1502, Mirdametinib (PD-0325901), Selumetinib, FCN-159, NFX-179 Gel, and others are expected to have a significant impact on the Neurofibromatosis Type 2 market in the coming years. •In November 2024, Alexion, AstraZeneca Rare Disease, and Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced positive topline results from the Phase 3 KOMET trial. This global, randomized, double-blind, placebo-controlled multicenter study is the largest of its kind in adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The findings revealed that KOSELUGO, an oral and selective MEK inhibitor, achieved a statistically significant and clinically meaningful improvement in objective response rate (ORR), the primary endpoint, compared to placebo in these patients. •In November 2024, SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company specializing in severe rare diseases and cancer, announced the publication of data from the pivotal Phase 2b ReNeu trial. The study evaluated mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The findings are now available online in the Journal of Clinical Oncology (JCO). •In August 2024, Healx, a clinical-stage biotech company leveraging AI to focus on rare diseases, has secured $47 million in Series C funding. The round was co-led by Silicon Valley's R42 Group and Atomico, one of Europe's prominent venture capital firms, with support from new and existing investors such as Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h, and VU Venture Partners. The funds will be utilized to advance Healx's pipeline of treatments targeting rare oncology, renal, and neurodevelopmental disorders, including progressing its lead candidate, HLX-1502, into a Phase 2 trial for neurofibromatosis Type 1 (NF1). Neurofibromatosis Type 2 Overview Neurofibromatosis Type 2 (NF2) is a rare genetic disorder characterized by the development of noncancerous tumors in the nervous system, primarily affecting the brain and spinal cord. The hallmark of NF2 is bilateral vestibular schwannomas (tumors on the auditory nerves), leading to hearing loss, tinnitus, and balance issues. Other manifestations may include meningiomas, ependymomas, and cataracts. NF2 is caused by mutations in the NF2 gene, which encodes the tumor suppressor protein merlin. It is typically inherited in an autosomal dominant pattern but can also arise from spontaneous mutations. Treatment focuses on symptom management, including surgery, radiation, and targeted therapies. Get a Free Sample PDF Report to know more about Neurofibromatosis Type 2 Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/neurofibromatosis-2-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Emerging Neurofibromatosis Type 2 Drugs Under Different Phases of Clinical Development Include: •REC-2282: Recursion Pharmaceuticals •VT3989: Vivace Therapeutics •HLX-1502: Healx Limited •Mirdametinib (PD-0325901): SpringWorks Therapeutics •Selumetinib: AstraZeneca •FCN-159: Fosun Pharmaceutical •NFX-179 Gel: NFlection Therapeutics, Inc. Neurofibromatosis Type 2 Route of Administration Neurofibromatosis Type 2 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as •Oral •Parenteral •Intravenous •Subcutaneous •Topical Neurofibromatosis Type 2 Molecule Type Neurofibromatosis Type 2 Products have been categorized under various Molecule types, such as •Monoclonal Antibody •Peptides •Polymer •Small molecule •Gene therapy Neurofibromatosis Type 2 Pipeline Therapeutics Assessment •Neurofibromatosis Type 2 Assessment by Product Type •Neurofibromatosis Type 2 By Stage and Product Type •Neurofibromatosis Type 2 Assessment by Route of Administration •Neurofibromatosis Type 2 By Stage and Route of Administration •Neurofibromatosis Type 2 Assessment by Molecule Type •Neurofibromatosis Type 2 by Stage and Molecule Type DelveInsight's Neurofibromatosis Type 2 Report covers around 5+ products under different phases of clinical development like •Late-stage products (Phase III) •Mid-stage products (Phase II) •Early-stage product (Phase I) •Pre-clinical and Discovery stage candidates •Discontinued & Inactive candidates •Route of Administration Further Neurofibromatosis Type 2 product details are provided in the report. Download the Neurofibromatosis Type 2 pipeline report to learn more about the emerging Neurofibromatosis Type 2 therapies at: https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some of the key companies in the Neurofibromatosis Type 2 Therapeutics Market include: Key companies developing therapies for Neurofibromatosis Type 2 are - AstraZeneca, Recursion Pharmaceuticals Inc., Vivace Therapeutics, Inc, Novartis Pharmaceuticals, GlaxoSmithKline, Ikena Oncology, SpringWorks Therapeutics, Inc, and others. Neurofibromatosis Type 2 Pipeline Analysis: The Neurofibromatosis Type 2 pipeline report provides insights into •The report provides detailed insights about companies that are developing therapies for the treatment of Neurofibromatosis Type 2 with aggregate therapies developed by each company for the same. •It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neurofibromatosis Type 2 Treatment. •Neurofibromatosis Type 2 key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. •Neurofibromatosis Type 2 Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. •Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neurofibromatosis Type 2 market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Neurofibromatosis Type 2 drugs and therapies- https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Neurofibromatosis Type 2 Pipeline Market Drivers •Advances in Genetic Research, Emerging Targeted Therapies, Increased Awareness and Diagnosis, Supportive Regulatory Environment, Collaboration and Funding, are some of the important factors that are fueling the Neurofibromatosis Type 2 Market. Neurofibromatosis Type 2 Pipeline Market Barriers •However, Rarity of the Disease, Complexity of Tumor Biology, High Costs of Development, Limited Treatment Options, Regulatory Challenges, and other factors are creating obstacles in the Neurofibromatosis Type 2 Market growth. Scope of Neurofibromatosis Type 2 Pipeline Drug Insight •Coverage: Global •Key Neurofibromatosis Type 2 Companies: Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics, AstraZeneca, Fosun Pharmaceutical, NFlection Therapeutics, Inc., and others •Key Neurofibromatosis Type 2 Therapies: REC-2282, VT3989, HLX-1502, Mirdametinib (PD-0325901), Selumetinib, FCN-159, NFX-179 Gel, and others •Neurofibromatosis Type 2 Therapeutic Assessment: Neurofibromatosis Type 2 current marketed and Neurofibromatosis Type 2 emerging therapies •Neurofibromatosis Type 2 Market Dynamics: Neurofibromatosis Type 2 market drivers and Neurofibromatosis Type 2 market barriers Request for Sample PDF Report for Neurofibromatosis Type 2 Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Table of Contents 1. Neurofibromatosis Type 2 Report Introduction 2. Neurofibromatosis Type 2 Executive Summary 3. Neurofibromatosis Type 2 Overview 4. Neurofibromatosis Type 2- Analytical Perspective In-depth Commercial Assessment 5. Neurofibromatosis Type 2 Pipeline Therapeutics 6. Neurofibromatosis Type 2 Late Stage Products (Phase II/III) 7. Neurofibromatosis Type 2 Mid Stage Products (Phase II) 8. Neurofibromatosis Type 2 Early Stage Products (Phase I) 9. Neurofibromatosis Type 2 Preclinical Stage Products 10. Neurofibromatosis Type 2 Therapeutics Assessment 11. Neurofibromatosis Type 2 Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Neurofibromatosis Type 2 Key Companies 14. Neurofibromatosis Type 2 Key Products 15. Neurofibromatosis Type 2 Unmet Needs 16 . Neurofibromatosis Type 2 Market Drivers and Barriers 17. Neurofibromatosis Type 2 Future Perspectives and Conclusion 18. Neurofibromatosis Type 2 Analyst Views 19. Appendix 20. About DelveInsight Related Reports: Neurofibromatosis Type 2 Market https://www.delveinsight.com/report-store/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Neurofibromatosis Type 2 Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), Neurofibromatosis Type 2 Epidemiology https://www.delveinsight.com/report-store/neurofibromatosis-2-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr DelveInsight's 'Neurofibromatosis Type 2 Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Latest Reports: •Prosthetic Heart Valve Market: https://www.delveinsight.com/report-store/prosthetic-heart-valve-market •Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market •Cardiac Arrythmia Market: https://www.delveinsight.com/report-store/ambulatory-arrhythmia-monitoring-devices-market •Alopecia Market: https://www.delveinsight.com/report-store/alopecia-areata-market •Optical Coherence Tomography Devices Market: https://www.delveinsight.com/report-store/optical-coherence-tomography-oct-devices-market •Prediabetes Market: https://www.delveinsight.com/report-store/prediabetes-market •Scoliosis Market: https://www.delveinsight.com/report-store/scoliosis-market •Psoriasis Market: https://www.delveinsight.com/report-store/psoriasis-market •Tendinitis Market: https://www.delveinsight.com/report-store/tendonitis-market •Vascular Closure Devices Market: https://www.delveinsight.com/report-store/vascular-closure-devices-market Contact Us: Gaurav Bora gbora@delveinsight.com +14699457679 Healthcare Consulting https://www.delveinsight.com/consulting-services About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. This release was published on openPR.

It seems Nvidia ( NVDA 1.18% ) is a victim of its own success. After another incredible quarter in which it doubled its earnings per share (EPS) year over year, the chipmaker's stock sank in the days following its Q3 numbers release. The fact is, expectations could hardly be higher. It's a good thing the company appears to be still firing on all cylinders. This isn't the first time it's been in this situation, and it's likely not the last. Nvidia saw its stock retreat nearly 20% in the weeks following its last release, only to gain nearly 35% from that low. There is good reason to remain optimistic, as the next year is full of major catalysts for the company. On Tuesday, Dec. 3, Nvidia joined other leading Artificial Intelligence (AI) firms to discuss the future of the industry with the investment community. The annual UBS Global Technology and AI Conference presents a chance for Nvidia to show continued leadership and make the case for why it has so much further to go. The event marries the technical with the practical, shedding light on just how impactful AI can be in creating real-world value. While one event is unlikely to move the needle, every chance the company -- and the industry, for that matter -- has a chance to make its case count. Here are three reasons why Nvidia is a buy as the event gets underway. 1. Nvidia's hardware continues to dominate Look, this is hardly news, but it bears repeating: the AI market is huge, growing rapidly, and there's ample reason to believe this will continue. PwC -- one of the "big four" accounting firms -- believes AI can add $15.7 trillion to the global economy by 2030. Statista predicts a compound annual growth rate (CAGR) for the total AI market of 28.3% through 2030. It's not just the analysts and talking heads that think so; CEOs from around Silicon Valley reiterated their commitment to AI and, more to the point, to spending billions of dollars on AI infrastructure. In Meta 's last earnings call , CEO Mark Zuckerberg stated that despite record capital expenditures , his company "should invest more" because AI will "accelerate [Meta's] core business" and "should have strong ROI over the next few years. That is great news for Nvidia. The company's chips supply the vast majority of the industry, and this market dominance is expected to continue in the foreseeable future. At this point, not even AMD can offer a chip that matches the performance of Nvidia's flagship chips. While this lead will likely shrink as time passes, it's doubtful Nvidia's would be leapfrogged. Nvidia has enormous resources -- in capital and talent -- it can use to defend its pole position. 2. Blackwell is here Blackwell, Nvidia's newest line of Superchips, releases this month, and samples are already in the hands of many of its major clients. The chips are incredibly powerful, more than twice as powerful as its current Hopper chips, and demand for them is at a fever pitch. CEO Jensen Huang described the demand as "staggering" and reports have indicated the company has been sold out of them for a full year. This is a big moment for Nvidia, and Wall Street is keen to see the company deliver a successful launch. If there are hiccups expected, Nvidia's executive team certainly didn't share them in its Q3 earnings call. The team painted a rosy picture of the next year and Blackwell's roll-out, expecting more Blackwells to ship than previously expected. I think there is a good chance that revenue from Blackwell will be even larger than Wall Street expects, but we will learn much more in the coming months. 3. Agentic AI is the next big thing The term has been thrown around a lot recently, but a big focus of Nvidia's call, apart from the launch of Blackwell, was the development and adoption of agentic AI -- essentially AI that can actually do , not just create. Jensen Huang likes to think of them as "AI coworkers" that can "assist employees in performing their jobs faster and better." I think that agentic AI if done well, is where the real value of AI lies. This is where true efficiencies can be made throughout organizations of all types. One of the ongoing questions in the market as a whole is whether AI can deliver value that justifies the enormous costs involved. If it can, this is where we will see it. Nvidia is ahead of this trend, offering "an operating platform of agentic AI," as Huang puts it, insisting that industry leaders are already using it to build "copilots" -- an industry term for AI helpers and agents.

No, These 34 Kitchen Items Are Not All Hype (And, Yes, They Make Perfect Gifts)

New spiking offence aims to bring law up to date, minister saysDuke's Diaz: QB Murphy faces internal discipline for raising middle fingers in Virginia Tech win